Focus: OrganOx is a UK-based biotechnology company specializing in organ transportation technology, primarily focused on normothermic machine perfusion systems for liver transplantation and acute liver failure. The company is publicly listed and operates at the intersection of transplant medicine and advanced medical devices.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Cooling — net -6 jobs in 30d
8 added, 14 removed. Slower than typical.
Best fit for candidates seeking impact-driven medical innovation in a public biotech with near-term commercial execution phases, but expect lower clinical trial complexity and narrower pipeline breadth than mid-cap peers.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for OrganOx
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from OrganOx's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo